◎ Sugi Atlas

Atlas / Drug / Sirolimus

Sirolimus

drug
On this page

Also known as (-)-rapamycinAY-22989FyarroHyftorL04AA10Npc-12gNSC-226080RapalimusRapamuneRapamycinSIROLIMUS COMPONENT OF SM-88WY-090217RAPAMYCIN (SIROLIMUS)AY 22989NSC-22608049,10,12,13,14,21,22,23,2423R*,26S*,27S*,34AR*]]-RAPAMYCINRAPAMYCIN (AY-22989)Sirolimus analogue

Summary

Sirolimus (CHEMBL413) is an approved small-molecule immunosuppressive agent (ATC S01XA23) targeting FKBP1A; indicated across 158 conditions including neoplasm and eye disorder; with CIViC clinical evidence for 24 variant-indication associations (e.g. STK11 Loss in lung non-small cell carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: S01XA23 (+2 more)
  • Targets: 1 (FKBP1A)
  • Indications: 158 conditions
  • Clinical trials: 571
  • Precision-oncology evidence (CIViC): 24 variant–indication associations
  • Chemistry: C51H79NO13

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL413
NameSirolimus
TypeSmall molecule
Max phase4
ChEBICHEBI:9168
ATCS01XA23, L04AH01, L01EG04
Molecular formulaC51H79NO13
InChIKeyQFJCIRLUMZQUOT-HPLJOQBZSA-N

SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](OC)C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)CC[C@@H](O)[C@H](OC)C1

ChEBI definition: A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.

Pharmacological roles (ChEBI): immunosuppressive agent, antineoplastic agent, antibacterial drug, mTOR inhibitor, anticoronaviral agent, geroprotector.

Other ChEBI roles (chemical / environmental): bacterial metabolite.

Also known as: (-)-rapamycin, AY-22989, Fyarro, Hyftor, L04AA10, Npc-12g, NSC-226080, Rapalimus, Rapamune, Rapamycin, Sirolimus, SIROLIMUS COMPONENT OF SM-88

Patent coverage: 46,327 distinct patent families (172,798 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
FKBP1AFKBP prolyl isomerase 1AInhibition9.721.5%P62942

Broader ChEMBL bioactivity targets: 34 (assay-derived). Sample: Pyruvate kinase PKM, Serine/threonine-protein kinase mTOR, Nuclear receptor ROR-gamma, Solute carrier organic anion transporter family member 1B1, Programmed cell death protein 4, Peptidyl-prolyl cis-trans isomerase FKBP1A, Amine oxidase [flavin-containing] A, Equilibrative nucleoside transporter 1, Peptidyl-prolyl cis-trans isomerase FKBP5, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 63 potent at pChembl ≥ 5 of 74 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
Q9JLN910.3IC500.05nMCHEMBL_ACT_19453018
MTOR10.3IC500.05nMCHEMBL_ACT_24962478
MTOR10.3IC500.05nMCHEMBL_ACT_25872951
MTOR10.22IC500.06nMCHEMBL_ACT_25442004
MTOR10IC500.1nMCHEMBL_ACT_20681615
MTOR10IC500.1nMCHEMBL_ACT_2200407
MTOR10IC500.1nMCHEMBL_ACT_25044933
MTOR10IC500.1nMCHEMBL_ACT_25937259
MTOR10IC500.1nMCHEMBL_ACT_29205856
FKBP1A9.89Kd0.13nMCHEMBL_ACT_26165916
FKBP1B9.7Kd0.2nMCHEMBL_ACT_15049565
FKBP1A9.7Kd0.2nMCHEMBL_ACT_25848532
FKBP1A9.7Ki0.2nMCHEMBL_ACT_992867
FKBP1A9.35IC500.45nMCHEMBL_ACT_1605332
MTOR9.35IC500.45nMCHEMBL_ACT_1615020
EIF4E9.3Kd0.5nMCHEMBL_ACT_5113953
FKBP1A9.22Ki0.6nMCHEMBL_ACT_18721920
MTOR9.22Kd0.6nMCHEMBL_ACT_18813393
FKBP1B9.22Kd0.6nMCHEMBL_ACT_26165919
FKBP1A9.22IC500.6nMCHEMBL_ACT_64601
MTOR9.1IC500.8nMCHEMBL_ACT_23207009
P268839IC501nMCHEMBL_ACT_18721939
FKBP1A8.96IC501.1nMCHEMBL_ACT_719989
MTOR8.8IC501.6nMCHEMBL_ACT_1659907
FKBP1A8.8IC501.6nMCHEMBL_ACT_18721917
FKBP1A8.8IC501.6nMCHEMBL_ACT_937964
FKBP58.52Ki3nMCHEMBL_ACT_12726904
MTOR8.46IC503.47nMCHEMBL_ACT_881846
FKBP58.43Kd3.7nMCHEMBL_ACT_25072928
FKBP48.38Kd4.2nMCHEMBL_ACT_25072934

Target pathways

Aggregated over 1 target gene(s): FKBP1A.

Top Reactome pathways

7 total, by targets touching each:

PathwayTargetsGenes
mTORC1-mediated signalling1FKBP1A
Calcineurin activates NFAT1FKBP1A
TGF-beta receptor signaling activates SMADs1FKBP1A
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)1FKBP1A
TGFBR1 LBD Mutants in Cancer1FKBP1A
Potential therapeutics for SARS1FKBP1A
SARS-CoV-1 activates/modulates innate immune responses1FKBP1A

Dominant GO biological processes

GO termTargets
heart morphogenesis1
protein folding1
‘de novo’ protein folding1
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion1
regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion1
negative regulation of transforming growth factor beta receptor signaling pathway1
regulation of protein localization1
negative regulation of activin receptor signaling pathway1
protein refolding1
T cell activation1
positive regulation of canonical NF-kappaB signal transduction1
regulation of immune response1
protein maturation1
ventricular cardiac muscle tissue morphogenesis1
heart trabecula formation1

Indications & clinical

Indications

158 indications (8 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
eye disorder4MONDO:0005328EFO:0003966
tuberous sclerosis4MONDO:0001734MONDO:0001734
graft versus host disease3MONDO:0013730EFO:0004599
hepatocellular carcinoma3MONDO:0007256EFO:0000182
fibroma3MONDO:0005167EFO:0002424
chronic kidney disease3MONDO:0005300EFO:0003884
Hodgkins lymphoma3MONDO:0004952EFO:0000183
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
inclusion body myositis3MONDO:0007827EFO:0007323
autosomal dominant polycystic kidney disease3MONDO:0004691EFO:1001496
lichen planus, oral3MONDO:0043923EFO:0008517
skin carcinoma3MONDO:0002656EFO:0009259
Birt-Hogg-Dube syndrome 13MONDO:0800445Orphanet:122
skin neoplasm3MONDO:0002531MONDO:0002898
breast neoplasm3MONDO:0021100MONDO:0007254
diabetic kidney disease3MONDO:0005016EFO:0000401
neurofibromatosis3MONDO:0021061EFO:0008514
type 1 diabetes mellitus3MONDO:0005147MONDO:0005147
lymphangioleiomyomatosis3MONDO:0011705MONDO:0011705
pachyonychia congenita3MONDO:0016471MONDO:0016471
lymphedema3MONDO:0019297MONDO:0019313
influenza3MONDO:0005812EFO:0007328
acute lymphoblastic leukemia2MONDO:0004967EFO:0000220
sarcoma2MONDO:0005089EFO:0000691
hypertensive disorder2MONDO:0005044EFO:0000537
plasma cell myeloma2MONDO:0009693EFO:0001378
age-related macular degeneration2MONDO:0005150EFO:0001365
primary cutaneous T-cell non-Hodgkin lymphoma2MONDO:0000607EFO:0002913
dry eye syndrome2MONDO:0006733EFO:1000906
systemic sclerosis2MONDO:0005100EFO:0000717
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
myelodysplastic syndrome2MONDO:0018881EFO:0000198
acute myeloid leukemia2MONDO:0018874EFO:0000222
diffuse large B-cell lymphoma2MONDO:0018905EFO:0000403
germ cell tumor2MONDO:0005040EFO:0000514
glioblastoma2MONDO:0018177EFO:0000519
leukemia2MONDO:0005059EFO:0000565
lymphoma2MONDO:0005062EFO:0000574
neuroblastoma2MONDO:0005072EFO:0000621
osteosarcoma2MONDO:0009807EFO:0000637
renal cell carcinoma2MONDO:0005086EFO:0000681
IgA glomerulonephritis2MONDO:0005342EFO:0004194
focal segmental glomerulosclerosis2MONDO:0100313EFO:0004236
vascular malformation2MONDO:0024291EFO:0006888
aplastic anemia2MONDO:0015909EFO:0006927
pineoblastoma2MONDO:0016722EFO:1000475
intermediate uveitis2MONDO:0006806EFO:1000986
posterior uveitis2MONDO:0006918EFO:1001119
gliosarcoma2MONDO:0016681EFO:1001465
mantle cell lymphoma2MONDO:0018876EFO:1001469
hematologic disorder2MONDO:0005570HP:0001871
arteriovenous malformations of the brain2MONDO:0007154Orphanet:46724
ovarian carcinoma2MONDO:0005140EFO:0001075
bronchitis2MONDO:0003781EFO:0009661
soft tissue sarcoma2MONDO:0018078EFO:1001968
kidney failure2MONDO:0001106EFO:1002048
brain aneurysm2MONDO:0005291EFO:0003870
polycystic kidney disease2MONDO:0020642EFO:0008620
anemia2MONDO:0002280MONDO:0002280
Castleman disease2MONDO:0015564MONDO:0015564
beta thalassemia2MONDO:0019402Orphanet:848
depressive disorder2MONDO:0002050MONDO:0002050
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
lupus nephritis2MONDO:0005556EFO:0005761
IgG4-related retroperitoneal fibrosis2MONDO:0018848MONDO:0018848
vitiligo2MONDO:0008661EFO:0004208
multiple system atrophy2MONDO:0007803EFO:1001050
inborn error of immunity2MONDO:0003778HP:0002721
amyotrophic lateral sclerosis2MONDO:0004976MONDO:0004976
Sturge-Weber syndrome2MONDO:0008501MONDO:0008501
sickle cell disease2MONDO:0011382MONDO:0011382
severe combined immunodeficiency2MONDO:0015974MONDO:0015974
neurofibromatosis type 12MONDO:0018975MONDO:0018975
sarcoidosis2MONDO:0019338MONDO:0019338
Fanconi anemia2MONDO:0019391MONDO:0019391
hemangioendothelioma2MONDO:0021121MONDO:0021121
liver disorder2MONDO:0005154EFO:0001421
neoplasm with perivascular epithelioid cell differentiation2MONDO:0006359EFO:1000464
autoimmune hemolytic anemia2MONDO:0020108EFO:1001264
systemic lupus erythematosus2MONDO:0007915MONDO:0007915
paraganglioma2MONDO:0000448EFO:1000453
blood platelet disease2MONDO:0002245MONDO:0002245
ovarian cancer2MONDO:0008170MONDO:0008170
choroidal neovascularization2MONDO:0810000MONDO:0810000
kidney disorder1MONDO:0005240EFO:0003086
diabetic retinopathy1MONDO:0005266EFO:0003770
HIV infectious disease1MONDO:0005109EFO:0000180
relapsing-remitting multiple sclerosis1MONDO:0005314EFO:0003929
rectal cancer1MONDO:0006519EFO:1000657
chronic myeloid leukemia1MONDO:0011996EFO:0000339
small cell lung carcinoma1MONDO:0008433EFO:0000702
squamous cell lung carcinoma1MONDO:0005097EFO:0000708
non-small cell lung carcinoma1MONDO:0005233EFO:0003060
anterior uveitis1MONDO:0006651EFO:1000811
metastatic prostate carcinoma1MONDO:0004956EFO:0000196
lung adenocarcinoma1MONDO:0005061EFO:0000571
plasma cell leukemia1MONDO:0018689EFO:0006475
fallopian tube carcinoma1MONDO:0006206EFO:1000251
malignant peripheral nerve sheath tumor1MONDO:0017827EFO:0000760
central nervous system neoplasm1MONDO:0006130EFO:1000158
scleritis1MONDO:0001718MONDO:0001718
hyperinsulinism1MONDO:0002177MONDO:0002177
pulmonary hypertension1MONDO:0005149MONDO:0005149
lung neoplasm1MONDO:0021117MONDO:0008903
hematopoietic and lymphoid system neoplasm1MONDO:0002334MONDO:0044881
acute lung injury1MONDO:0015796EFO:0004610
acute respiratory distress syndrome1MONDO:0006502EFO:1000637
Gaucher disease1MONDO:0018150Orphanet:77260
desmoid tumor1MONDO:0007608EFO:0009907
heart failure1MONDO:0005252EFO:0003144
thalassemia1MONDO:0000984EFO:1001996
Parkinson disease1MONDO:0005180MONDO:0005180
alcohol abuse1MONDO:0002046MONDO:0007079
frontotemporal dementia1MONDO:0017276MONDO:0017276
chronic granulomatous disease1MONDO:0018305MONDO:0018305
Sjogren syndrome1MONDO:0010030EFO:0000699
plasma cell neoplasm1MONDO:0004959EFO:0000200
leiomyosarcoma1MONDO:0005058EFO:0000564
prostate carcinoma1MONDO:0005159EFO:0001663
eosinophilic esophagitis1MONDO:0005361EFO:0004232
respiratory failure1MONDO:0021113EFO:0009686
panuveitis1MONDO:0017255EFO:1001082
fallopian tube neoplasm1MONDO:0021092MONDO:0002158
Alzheimer disease1MONDO:0004975MONDO:0004975
glioma1MONDO:0021042MONDO:0021637
pemphigus0MONDO:0006594EFO:1000749
lymphoid leukemia0MONDO:0005402EFO:0004289

29 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 571.

Phase distribution

PhaseTrials
PHASE2185
PHASE1100
PHASE1/PHASE283
PHASE476
PHASE350
Not specified37
PHASE2/PHASE322
EARLY_PHASE118

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05193565PHASE4ACTIVE_NOT_RECRUITINGStudy to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients
NCT06236022PHASE4RECRUITINGThe Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT06722586PHASE4RECRUITINGSirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
NCT07426484PHASE4NOT_YET_RECRUITINGCosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
NCT07542314PHASE4NOT_YET_RECRUITINGStudy to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
NCT00044720PHASE4COMPLETEDStudy Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
NCT00118742PHASE4COMPLETEDLiver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
NCT00121810PHASE4COMPLETEDKidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients
NCT00123331PHASE4COMPLETEDRapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation
NCT00129961PHASE4COMPLETEDStudy Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
NCT00166712PHASE4TERMINATEDA Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
NCT00166816PHASE4UNKNOWNThe Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients
NCT00166829PHASE4UNKNOWNThe Effect of Sirolimus on the Pharmacokinetics of Tacrolimus
NCT00166842PHASE4UNKNOWNSirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
NCT00188955PHASE4COMPLETEDPilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant
NCT00195429PHASE4COMPLETEDA Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients
NCT00195481PHASE4COMPLETEDStudy Evaluating Sirolimus in Kidney Transplant Recipients in India
NCT00223028PHASE4COMPLETEDInvestigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation
NCT00223678PHASE4COMPLETEDMycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
NCT00252655PHASE4UNKNOWNUse of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients
NCT00254709PHASE4COMPLETEDStudy Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients
NCT00261820PHASE4COMPLETEDStudy Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients
NCT00266123PHASE4COMPLETEDStudy Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients
NCT00275522PHASE4COMPLETEDThe Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.
NCT00275535PHASE4COMPLETEDThe Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
NCT00282217PHASE4COMPLETEDStudy Evaluating Sirolimus in the Treatment of Kidney Transplant
NCT00290069PHASE4UNKNOWNRenal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)
NCT00305396PHASE4COMPLETEDCalcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation
NCT00306397PHASE4COMPLETEDPilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients
NCT00321906PHASE4COMPLETEDComparison of Sirolimus and Azathioprine in Lung Transplantation
NCT00352092PHASE4COMPLETEDPilot Study for HLA Identical Living Donor Renal Transplant Recipients
NCT00369382PHASE4COMPLETEDStudy Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
NCT00374647PHASE4COMPLETEDStudy to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts
NCT00452361PHASE4TERMINATEDStudy Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient
NCT00493194PHASE4UNKNOWNFibrosis in Renal Allografts
NCT00507793PHASE4COMPLETEDStudy Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus
NCT00552669PHASE4COMPLETEDStudy of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents
NCT00556933PHASE4COMPLETEDImproved Induction and Maintenance Immunosuppression in Kidney Transplantation
NCT00598533PHASE4COMPLETEDEfficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary Restenosis
NCT00681213PHASE4COMPLETEDTacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation

Clinical evidence (CIViC)

Variant × indication × effect (24 predictive associations from 28 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
STK11 LossLung Non-small Cell CarcinomaSensitivity/ResponseSirolimusCIViC BEID2314 +3
EGFR P753SSkin Squamous Cell CarcinomaSensitivity/ResponseCetuximab + SirolimusCIViC CEID1089
STK11 LossPeutz-Jeghers SyndromeSensitivity/ResponseSirolimusCIViC DEID1618 +1
CRLF2 RearrangementAcute Lymphoblastic LeukemiaSensitivity/ResponseSirolimusCIViC DEID11097
ERBB2 Y772_A775DUPLung Non-small Cell CarcinomaSensitivity/ResponseSirolimus + AfatinibCIViC DEID960
FBXW7 Loss-of-functionCancerSensitivity/ResponseSirolimusCIViC DEID1632
FLCN LossRenal CarcinomaSensitivity/ResponseSirolimusCIViC DEID5991
IGH::CRLF2 Fusion AND JAK2 R683GB-lymphoblastic Leukemia/lymphoma With BCR-ABL1Sensitivity/ResponseSirolimusCIViC DEID7641
MTOR C1483FSolid TumorSensitivity/ResponseSirolimusCIViC DEID7324
MTOR C1483YT-cell Acute Lymphoblastic LeukemiaSensitivity/ResponseSirolimusCIViC DEID1320
MTOR E1799KClear Cell Renal Cell CarcinomaSensitivity/ResponseSirolimusCIViC DEID1321
MTOR F1888LSolid TumorSensitivity/ResponseSirolimusCIViC DEID7325
MTOR L2230VSolid TumorSensitivity/ResponseSirolimusCIViC DEID7327
MTOR S2215FSolid TumorSensitivity/ResponseSirolimusCIViC DEID7326
MTOR S2215YEndometrial AdenocarcinomaSensitivity/ResponseSirolimusCIViC DEID1319
MTOR T1977KSolid TumorSensitivity/ResponseSirolimusCIViC DEID7323
NF1 MutationSkin MelanomaSensitivity/ResponseMirdametinib + SirolimusCIViC DEID1469
PIK3CA E542KBreast CancerSensitivity/ResponseSirolimusCIViC DEID311
STK11 LossLung Non-small Cell CarcinomaSensitivity/ResponseEverolimus + SirolimusCIViC DEID1620
TSC1 Frameshift TruncationLung Non-small Cell CarcinomaSensitivity/ResponseSirolimusCIViC DEID154
MTOR A2034VBreast CancerResistanceSirolimusCIViC DEID1547
MTOR F2108LBreast CancerResistanceSirolimusCIViC DEID1543
MTOR M2327IBreast CancerResistanceRapaLink-1 + SirolimusCIViC DEID1545
RHEB Y35NKidney CancerResistanceSirolimusCIViC DEID6340

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

5 molecules share ≥1 primary target. Top 5 by shared-target count:

MoleculeSourceStatusShared targets
CYCLOSPORINEChEMBLPhase 4 (approved)FKBP1A
TACROLIMUSChEMBLPhase 4 (approved)FKBP1A
THIABENDAZOLEChEMBLPhase 4 (approved)FKBP1A
BIRICODARChEMBLPhase 2FKBP1A
CYCLOHEXIMIDEChEMBLPhase 2FKBP1A

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot